American Capital Management Inc. Trims Stake in OraSure Technologies, Inc. (NASDAQ:OSUR)

American Capital Management Inc. trimmed its holdings in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 78.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 251,846 shares of the medical instruments supplier's stock after selling 939,467 shares during the quarter. American Capital Management Inc. owned approximately 0.34% of OraSure Technologies worth $1,075,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of OraSure Technologies by 1.9% in the first quarter. Vanguard Group Inc. now owns 5,409,028 shares of the medical instruments supplier's stock valued at $33,266,000 after purchasing an additional 99,572 shares during the period. Renaissance Technologies LLC boosted its holdings in OraSure Technologies by 20.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,288,443 shares of the medical instruments supplier's stock worth $9,749,000 after buying an additional 391,100 shares during the last quarter. Acadian Asset Management LLC increased its stake in OraSure Technologies by 38.1% during the 2nd quarter. Acadian Asset Management LLC now owns 2,195,582 shares of the medical instruments supplier's stock worth $9,349,000 after buying an additional 605,324 shares in the last quarter. Millennium Management LLC increased its stake in OraSure Technologies by 727.5% during the 2nd quarter. Millennium Management LLC now owns 2,021,126 shares of the medical instruments supplier's stock worth $8,610,000 after buying an additional 1,776,867 shares in the last quarter. Finally, American Century Companies Inc. raised its holdings in shares of OraSure Technologies by 30.1% during the second quarter. American Century Companies Inc. now owns 1,809,897 shares of the medical instruments supplier's stock valued at $7,710,000 after acquiring an additional 418,603 shares during the last quarter. Institutional investors and hedge funds own 93.50% of the company's stock.

OraSure Technologies Price Performance

Shares of NASDAQ:OSUR traded down $0.04 during midday trading on Friday, hitting $3.80. The company had a trading volume of 418,137 shares, compared to its average volume of 697,116. OraSure Technologies, Inc. has a twelve month low of $3.72 and a twelve month high of $8.45. The stock has a market cap of $283.46 million, a price-to-earnings ratio of 25.33 and a beta of 0.05. The business's 50-day simple moving average is $4.09 and its 200-day simple moving average is $4.29.

OraSure Technologies (NASDAQ:OSUR - Get Free Report) last issued its earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.02. The business had revenue of $39.92 million during the quarter, compared to the consensus estimate of $38.97 million. OraSure Technologies had a return on equity of 3.55% and a net margin of 5.07%. The company's revenue for the quarter was down 55.2% on a year-over-year basis. During the same period last year, the company earned $0.27 EPS. As a group, sell-side analysts forecast that OraSure Technologies, Inc. will post -0.09 EPS for the current year.

Analyst Ratings Changes

OSUR has been the subject of several research reports. StockNews.com upgraded OraSure Technologies from a "hold" rating to a "buy" rating in a research report on Friday, October 4th. Evercore ISI lifted their target price on shares of OraSure Technologies from $4.50 to $5.00 and gave the stock an "in-line" rating in a research note on Wednesday, August 7th.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.